Masimo (MASI) Restructuring Costs (2013 - 2017)
Masimo's quarterly Restructuring Costs came in at $10.5 million in Q4 2017, up 303.85% quarter-over-quarter from $2.6 million in Q4 2013.
Masimo has reported Restructuring Costs for 2 years, with the latest figure at $10.5 million in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Masimo | 9.32 Bn | 9.20 Bn | 250.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 30, 2017 | 10.50 Mn |
| Dec 28, 2013 | 2.60 Mn |